Join Dr Jorg Taubel at the 2015 Annual Meeting of the ACCP (American College of Clinical Pharmacology) for his latest scientific poster presentations on cost saving strategies for early phase drug development.Sunday, 27 September, 17h30 to 19h30 - Abstract Poster Board Number 55Confirmation of the Cardiac Safety of Rupatadine in a SAD and MAD study in Japanese healthy subjects using intensive ECG assessmentsMonday, 28 September, 17h30 to 19h30 - Abstract Poster Board Number 66Pharmacokinetics, safety and tolerability of Rupatadine in healthy Japanese volunteersA global audience will come together for presentations from an international Faculty of over 75 speakers in three Pre-meeting Workshops and 12 Symposia on a series of topics ranging from research and drug development to patient care.

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event